Haemostatic problems in acute promyelocytic leukaemia

Blood Reviews

Volumn 20, Issue 6, 2006, Pages 289-297

  Arbuthnot, Carolina ^a   Wilde, Jonathan T ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acute promyelocytic leukaemia; All trans retinoic acid (ATRA); Bleeding diathesis; Disseminated intravascular coagulation; Fibrinolysis

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BLOOD CLOTTING FACTOR 10A INHIBITOR; CANCER PROCOAGULANT; CYTOKINE; FONDAPARINOX; FRESH FROZEN PLASMA; HEPARIN; LIPOCORTIN 2; LOW MOLECULAR WEIGHT HEPARIN; RETINOIC ACID; THROMBOMODULIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ARTICLE; BLAST CELL; BLEEDING DISORDER; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL MEMBRANE; CELL SURFACE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISSEMINATED INTRAVASCULAR CLOTTING; DOWN REGULATION; FIBRINOLYSIS; HEMOSTASIS; HUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL RATE; UPREGULATION;

CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; HEMORRHAGIC DISORDERS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; TRETINOIN;

EID: 33750627287     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2006.04.001     Document Type: Article

References (90)

1. Tornebohm E., Blomback M., Lockner D., Egberg N., and Paul C. Bleeding complications and coagulopathy in acute leukaemia. Leuk Res 16 (1992) 1041-1048
2. Lisiewicz J. Disseminated intravascular coagulation in acute leukaemia. Seminars in Thrombos and Haemostas 14 (1988) 339-350
3. Rodeghiero F., Avvisati G., Castaman G., Barbui T., and Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukaemia: A GIMEMA retrospective study in 268 consecutive patients. Blood 75 (1990) 2112-2117
4. Warrell R.P., de The H., Wang Z.-.Y., and Degos L. Acute promyelocytic leukaemia. N Engl J Med 329 (1993) 177-189
5. Falanga A., and Rickles F.R. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Practice & Research Clin Haematol 16 (2003) 463-482
6. Tallman M.S., Brenner B., and de la Serna J. Meeting report. Leuk Res 29 (2005) 347-351
7. Wilde J.T., and Davies J.M. Haemostatic Problems in Acute Leukaemia. Blood Reviews 4 (1990) 245-251
8. Myers T.J., Rickles F.R., Barb C., and Cronlund M. Fibrinopeptide A in acute leukaemia: relationship of activation of blood coagulation to disease activity. Blood 57 (1981) 518-525
9. Bauer K.A., and Rosenberg R.D. Thrombin generation in acute promyelocytic leukaemia. Blood 64 (1984) 791-796
10. Bosclair M.D., Lane D.A., Wilde J.T., Ireland H., Preston F.E., and Ofosu F.A. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrinogen/fibrin fragment E. Br J Haematol 74 (1990) 471-479
11. Tallman M.S., Hakimian D., KWaan H.C., and Rickles F.R. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukaemia. Leuk Lymph 11 (1993) 27-36
12. Falanga A., Iacoviello L., Evangelista V., et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia given all-trans-retinoic acid. Blood 86 (1995) 1072-1081
13. Dombret H., Scrobohaci M.L., Ghorra P., et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 7 (1993) 2-9
14. Dombret H., Scrobohaci M.L., Daniel M.T., et al. In vivo thrombin and plasmin activites in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 9 (1995) 19-24
15. Polliak A. Acute promyelocytic leukemia with disseminated intravascular coagulation. Am J Clin Path 56 (1971) 155-161
16. Gralnick H.R., Bagley J., and Abrell E. Heparin treatment for the haemorrhagic diathesis of acute promyelocytic leukemia. Am J Med 52 (1972) 167-174
17. Gouault-Heilman M., Chardon E., Sultan E., and Josso F. The procoagulant factor of leukemic promyelocytes: Demonstration of immunologic cross-reactivity with human brain tissue factor. Br J Haematol 30 (1975) 151-158
18. Andoh K., Kubota T., Takada M., Tanaka H., Kobayashi N., and Maekawa T. Tissue factor activity in leukemia cells. Special reference to disseminated intravascular coagulation. Cancer 59 (1987) 748-754
19. Bauer K.A., Conway E.M., Bach R., Konigsberg W.H., Griffin J.D., and Demetri G. Tissue factor gene expression in acute myeloblastic leukemia. Throm Res 56 (1989) 425-430
20. Tanaka M., and Yamanishi H. The expression of tissue factor antigen and activity on the surface of leukemia cells. Leuk Res 17 (1997) 103-111
21. Pedrera C.L., Jardi M., Malogon M., et al. TF and u-PAR and bleeding complications in leukemic patients. Thrombos Haemostas 77 (1997) 62-70
22. Falanga A., Alessio M.G., Donati M.B., and Barbui T. A new procoagulant in acute leukemia. Blood 71 (1988) 870-875
23. Donati M.B., Falanga A., Consonni R., et al. Cancer procoagulant in acute non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost 64 (1990) 11-16
24. Vellenga E., and Mulder N.H. Normal levels of antithrombin III in acute leukaemia complicated by coagulopathy. Acta Haematologica 63 (1980) 336-338
25. Sandler R.M., Liebman H.A., Patch M.J., Teitelbaum A., Levine A.M., and Feinstein D.I. Antithrombin III and anti-activated factor X activity in patients with acute promyelocytic leukaemia and disseminated intravascular coagulation treated with heparin. Cancer 50 (1982) 2106-2110
26. 2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 70 (1988) 43-48
27. Speiser W., Pabinger-Fasching I., Kyrle P.A., et al. Hemostatic and fibrinolytic parameters in patients with acute myeloid leukaemia: Activation of blood coagulation, fibrinolysis and unspecific proteolysis. Blut 61 (1990) 298-302
28. Plow E.F., and Edgington T.S. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56 (1975) 30-38
29. Nossel H.L., Hurlet-Jensen A., Lui C.Y., Koehn J.A., and Canfield R.E. Fibrinopeptide release from fibrinogen. Ann N Y Acad Sci 408 (1983) 269-277
30. Bennett M., Parker A.C., and Ludlam C.A. Platelet and fibrinogen survival in acute promyelocytic leukaemia. BMJ 2 (1976) 565
31. 2-antiplasmin complexes in bleeding disorders characterised by primary or secondary fibrinolysis. Br J Haematol 56 (1984) 545-556
32. Imaoka S., Ueda T., Shibata H., et al. Fibrinolysis in patients with acute promyelocytic leucemia and disseminated intravascular coagulation during heparin therapy. Cancer 58 (1986) 1736-1738
33. 2-plasmin inhibitor deficiency. Ann Intern Med 105 (1986) 873-877
34. Reddy V.B., Kowal-Vern A., Hoppensteadt D.A., et al. Global and hemostatic markers in acute leukemia. Am J Clin Pathol 94 (1990) 397-403
35. Sakata Y., Murakami T., Noro A., Mori K., and Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 77 (1991) 1949-1957
36. Gralnick H.R., and Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic lekuemia. Br J Haematol 24 (1973) 89-99
37. Bennett B., Booth N.A., Croll A., and Dawson A.A. The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 71 (1989) 511-517
38. Tapiovaara H., Alitalo R., Stephens R., Myohanen H., Ruutu T., and Vaheri A. Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukaemia patients. Blood 82 (1993) 914-919
39. Stephens R., Alitalo R., Tapiovaara H., Vaheri A., et al. Production of an active urokinase by leukaemia cells. A novel distinction from cell lines of solid tumors. Leuk Res 12 (1988) 419-422
40. Menell J.S., Cesarman G.M., Jacovina A.T., McLaughlin M.A., Lev E.A., and Hajjar K.A. Annexin II and bleeding in acute promyelocytic leukaemia. N Engl J Med 340 (1999) 994-1004
41. Hajjar K.A., Jacovina A.T., and Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 269 (1994) 21191-21197
42. Hajjar K.A., and Menell J.S. Annexin II: a novel mediator of cell surface plasmin generation. Ann N Y Acad Sci 811 (1997) 337-349
43. Cesarman G.M., Guevara C.A., and Hajjar K.A. An endotelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA dependent plasminogen activation. J Biol Chem 269 (1994) 21198-21203
44. Griffin J.D., Rambaldi A., Vellenga E., Young D.C., Ostapovicz D., and Cannistra S.A. Secretion of interleukin-1 by acute myeloid cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood 70 (1987) 1218-1221
45. Cozzolino F., Torcia M., Miliani A., et al. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. Am J Med 84 (1988) 240-250
46. Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S., and Gimbrone Jr. M.A. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium.: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 83 (1986) 4533-4537
47. Moore K.L., Esmon C.T., and Esmon N.L. Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture. Blood 73 (1989) 159-165
48. Nachman R.L., Hajjar K.A., Siverstein R.L., and Dinarello C.A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 163 (1986) 1595-1600
49. Egbring R., Schmidt W., Fuchs G., and Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 49 (1977) 219-231
50. Schmidt W., Egbring R., and Havemann K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isoltaed clotting factors. Thromb Res 6 (1975) 315-326
51. Brower M.S., and Harpel P.C. Proteolytic cleavage and inactivation of a2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 257 (1982) 9849-9854
52. Sterrenberg L., van Liempt G.J., Nieuwenhuizen W., and Hermans J. Anticoagulant properties of purified X-like fragments of human fibrinogen produced by degradation with leukocyte elastase. Thromb Haemost 51 (1984) 398-402
53. Oudijk E.-.J.D., Nieuwenhuizen H.K., Bos R., and Fijnheer R. Elastase mediated fibrinolysis in acute promyelocytic leukaemia. Thromb Haemost 83 (2000) 906-908
54. Federici A.B., Berkowitz S.D., Lattuada A., and Mannucci P.M. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 81 (1993) 720-725
55. Federici A.B., Falanga A., Lattuada A., Di Rocco N., Barbui T., and Mannucci P.M.M. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukemia by treatment with all-trans-retinoic acid. Br J Haematol 92 (1996) 733-739
56. Fenaux P., Chomienne C., and Degos L. Treatment of acute promyelocytic leukaemia. Best Practice & Research Clin Haematol 14 (2001) 153-174
57. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100 (2002) 4298-4302
58. Arlin Z., Kempin S., and Mertelsmann R. Primary therapy of acute promyelocytic leukemia: role of amsacrine and daunorubicin based therapy. Blood 63 (1984) 211-212
59. Degos L., Dombret H., Chomienne C., et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukaemia. Blood 85 (1995) 2643-2653
60. Cordonnier C., Vernant J.P., and Brun B. Acute promyelocytic leukaemia in 57 previously untreated patients. Cancer 55 (1985) 18-25
61. Kantarjian H., Keating M., and Walters R. Acute promyelocytic leukaemia. MD Anderson Hospital Experience. Am J Med 80 (1986) 789-797
62. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 122 (2003) 10-23
63. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozenplasma, cryoprecipitate and cryosupernatant. Br J Haematol 126 (2004) 11-28
64. Levi M., and ten Cate H. Disseminated intravascular coagulation. N Engl J Med 341 (1999) 586-592
65. Grignani F., Fagioli M., Alcalay M., et al. Acute promyelocytic leukemia: From genetics to treatment. Blood 83 (1994) 10-25
66. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Fenaux P., and Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukaemia. Blood 76 (1990) 1704-1709
67. Kawai Y., Watanabe K., Kizaki M., et al. Rapid improvement of coagulopathy by all-trans-retinoic acid in acute promyelocytic leukemia. Am J Hematol 46 (1994) 184-188
68. Fenaux P., Le Deley M.C., Chastang C., et al. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomised trial. Blood 82 (1993) 3241-3249
69. Keane T.J., Gorman A.M., O'Connell L.G., and Fenelly J.J. Epsilon-amino-caproic acid in the management of acute promyelocytic leukaemia. Acta Haematol 56 (1976) 202-204
70. Schwartz B.S., Williams E.C., Conlan M.G., and Mosher D.F. Epsilon-aminocaproic aicd in the treatment of patients with acute promyelocytic leukaemia and acquired alpha2-plasmin inhibitor deficiency. Ann Int Med 105 (1986) 873-877
71. Avvisati G., ten Cate J.W., Buller H.R., and Mandelli F. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 2 (1989) 122-124
72. Sugawara T., Okuda M., Yamaguchi Y., Endo K., and Yoshinaga K. Successful treatment with tranexamic acid for severe bleeding in acute promyelocytic leukemia. Acta Haematol 87 (1992) 109
73. Runde V., Aul C., Sudhoff T., Heyll A., and Schneider W. All-trans retinoic acid: not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia. Blood 79 (1992) 534-535
74. Forjaz De Lacenda J., Alves Do Carmo J., Lurdes Guerna M., Geraldes J., and Forjaz De Lacerda J.M. Multiple thrombosis in acute promyelocytic leukaemia after tretoin. Lancet 342 (1993) 114
75. Hashimoto S., Koike T., and Tatewaki W. Fatal thromboembolism in acute promyelocytoc leukaemia during all-trans retinoic acid therapy combined with ant-fibrinoytic therapy for prophylaxis of hemorrhage. Leukemia 8 (1994) 1113-1115
76. Escudier S.M., Kantarjian H.M., and Estey E.H. Thrombosis in patients with acute promyelocytic leukaemia treated with and without all-trans retinoic acid. Leuk Lymphoma 20 (1996) 435-439
77. Koyama T., Hirosawa S., Kawamata N., Tohda S., and Aoki N. All-trans-retinoic acid upregulates thrombomodulin and downregulates tissue factor expression in acute promyelocytic leukaemia cells. Distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood 84 (1994) 3001-3009
78. De Stefano V., Teofili L., Sica S., et al. Effect of all-trans-retinoic on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 86 (1995) 3535-3541
79. Saito T., Koyama T., Nagata K., Kamiyama R., and Hirosawa S. Anticoagulant effects of retionoic acids on leukaemia cells. Blood 87 (1996) 657-665
80. Falanga A., Consonni R., Marchetti M., et al. Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid. Leukemia 8 (1994) 156-159
81. Zhu J., Guo W.M., Yao Y.Y., et al. Tissue factors on acute promyelocytic leukaemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 13 (1999) 1062-1070
82. Falanga A., Consonni R., Marchetti M., et al. Cancer procoagulant and tissue factor are differently modulated by all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia cells. Blood 92 (1998) 143-151
83. Tapiovaara H., Matikainen S., Hurme M., and Vaheri A. Induction of differentiation of promyelocytic NB4 cells by retinoic acid is associated with rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 83 (1994) 1883-1891
84. Barbui T., Finazzi G., and Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 91 (1998) 3093-3102
85. Dubois C., Schlageter M.H., de Gentile, et al. Modulation of IL-8, IL-1β and G-CSF by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 8 (1994) 1750-1757
86. Falanga A., Marchetti M., Giovanelli S., and Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induce by a human promyelocytic leukemia-derived cell line (NB4). Blood 87 (1996) 613-617
87. Ishii H., Horie S., Kizaki K., and Kazama M. Retinoic acid counteracts both the downregulation of thrombomodulin and the induction of tissue factor in cultured endothelial cells exposed to tumor necrosis factor. Blood 80 (1992) 2556-2562
88. Horie S., Kizaki K., Ishii H., and Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anticoagulant glycoprotein, on human endothelial cells: Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP. Biochem J 281 (1992) 149-154
89. Kooistra T., Opdenberg J.P., Toet K., Hendriks H.F.J., van den Hoogen R.M., and Emeis J.J. Stimulation of tissue-type plasminogen activators synthesis by retionoids in cultured human endothelial cells and rat tissues in vivo. Thromb Haemost 65 (1991) 565-572
90. Medh R.D., Santell L., and Levin E.G. Stimulation of tissue plasminogen activator production by reinoic acid: Synergistic effect on protein kinase C-mediated activation. Blood 80 (1992) 981-987